Title: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
Headings: Staphylococcus saprophyticus
: Which beta-lactam?

International Journal of Infectious Diseases
Short Communication
Staphylococcus saprophyticus: Which beta-lactam?
Highlights
Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
Methods
Results
Discussion
Conflict of interest/funding
References

Content: •
This study analysed the epidemiology of S. saprophyticus urinary tract infections. •
Susceptibility of S. saprophyticus to ceftriaxone was studied. •
A high rate of ineffective empirical antibiotic therapy for S. saprophyticus was noted. •
High ceftriaxone minimum inhibitory concentrations were noted for methicillin-susceptible S. saprophyticus. Abstract
Background
Staphylococcus saprophyticus is resistant to the drugs most often used for the empirical treatment of urinary tract infections (UTI). The adequacy of antimicrobial treatments prescribed for UTI due to S. saprophyticus is not usually questioned. This study described the epidemiology of such infections and assessed the susceptibility of S. saprophyticus to ceftriaxone and amoxicillin–clavulanic acid. Methods
Methicillin-susceptible S. saprophyticus (MSSS) isolated from clinical samples between November 2014 and July 2016 were included. Clinical data were recorded. The minimum inhibitory concentrations (MICs) of amoxicillin–clavulanic acid and ceftriaxone were measured for these MSSS strains and for 17 randomly selected methicillin-susceptible Staphylococcus aureus (MSSA) strains.